NCT04588545 2026-02-09
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT07264569 2025-12-04
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001
Henan Cancer Hospital
Phase 1/2 Recruiting
NCT01373710 2025-11-24
HIT
Institut Curie
Phase 1/2 Completed
NCT06462092 2025-09-29
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06462222 2025-09-29
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Guangzhou Medical University
Phase 1/2 Active not recruiting
NCT07177950 2025-09-17
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
Peking University Cancer Hospital & Institute
Phase 1/2 Not yet recruiting
NCT06762080 2025-05-20
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06809517 2025-05-20
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06809530 2025-05-18
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT05289908 2025-05-04
Intrathecal Pemetrexed for Leptomeningeal Metastasis
The First Hospital of Jilin University
Phase 1/2 Completed